Drug Retention Rate and Predictive Factors of Drug Survival for Interleukin-1 Inhibitors in Systemic Juvenile Idiopathic ArthritisJurgen Sota, Luca Cantarini, Alma Nunzia Olivieri et al.|Frontiers in Pharmacology|2019Cited by 616
Clinical Features, Treatment, and Outcome of Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A Multinational, Multicenter Study of 362 PatientsFrancesca Minoia, Angelo Ravelli, Sergio Davì et al.|Arthritis & Rheumatology|2014Cited by 430
A Snapshot on the On-Label and Off-Label Use of the Interleukin-1 Inhibitors in Italy among Rheumatologists and Pediatric Rheumatologists: A Nationwide Multi-Center Retrospective Observational StudyAntonio Vitale, Luca Cantarini, Antonella Insalaco et al.|Frontiers in Pharmacology|2016Cited by 88
Safety profile of the interleukin-1 inhibitors anakinra and canakinumab in real-life clinical practice: a nationwide multicenter retrospective observational studyMario Messina, Jurgen Sota, Antonio Vitale et al.|Clinical Rheumatology|2018Cited by 82
Anakinra Drug Retention Rate and Predictive Factors of Long-Term Response in Systemic Juvenile Idiopathic Arthritis and Adult Onset Still DiseaseJurgen Sota, Luca Cantarini, Donato Rigante et al.|Frontiers in Pharmacology|2019Cited by 45